Exchange: NASDAQ·Updated 04:00 PM EDT

BRVE Braveheart Bio Inc.

$19.21
$0.50
(2.67%)
Today
EarningsNov 12
Mkt Cap$1.73B
Vol333,743.00

About BRVE

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
50

Neutral Sentiment

How do you feel about BRVE?

Advertisement|Remove ads.